SiSaf Ltd

SiSaf Ltd, with the slogan "Delivering on the promise of RNA therapeutics," is a biotechnology company specializing in RNA delivery and therapeutics. The company's proprietary Bio-Courier® technology sets it apart by leveraging organic materials with inorganic bioabsorbable silicon to overcome the limitations of existing RNA delivery technologies. SiSaf's Bio-Courier portfolio features silicon stabilized hybrid lipid nanoparticles (sshLNP) that enhance the stability, safety, and transfection efficiency of RNA. These technological advancements enable SiSaf to develop a pipeline of RNA therapeutics tailored to address rare genetic disorders, further underscored by its proactive engagement in research partnerships. Established in 2008, SiSaf is headquartered in Guildford, United Kingdom, and is led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert. As a venture capital-backed private company, SiSaf secured a significant $13.20M Series B investment on 26 November 2020, with Vickers Venture Partners as the prominent investors. The company's integrated research labs and bio-analytical facilities, coupled with a scalable technology infrastructure and a growing patent estate, position SiSaf as a promising player in the biotechnology, health care, and pharmaceutical industries. SiSaf's groundbreaking approach to RNA therapeutics, bolstered by substantial financial backing and strategic partnerships, signifies its potential for disruptive innovation and transformative impact in the biotechnology landscape.